Neuronal Ceroid Lipofuscinosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of neuronal ceroid lipofuscinosis (NCL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of NCL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s NCL forecast will answer the following question:
- How will demographic trends, such as changes in birth rates and population size, affect the epidemiology of NCL over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts five NCL populations as follows:
- Diagnosed prevalence of NCL.
- Diagnosed prevalence of NCL 1.
- Diagnosed prevalence of NCL 2.
- Diagnosed prevalence of NCL 3.
- Diagnosed prevalence of NCL 4.
Note: Coverage may vary by country.
Table of contents
- Neuronal Ceroid Lipofuscinosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of neuronal ceroid lipofuscinosis)
- Diagnosed prevalence of neuronal ceroid lipofuscinosis
- Diagnosed prevalence of neuronal ceroid lipofuscinosis 1
- Diagnosed prevalence of neuronal ceroid lipofuscinosis 2
- Diagnosed prevalence of neuronal ceroid lipofuscinosis 3
- Diagnosed prevalence of neuronal ceroid lipofuscinosis 4
- Risk / protective factors applied to disease forecast models
- Reference materials
Saayali Khankari, B.D.S, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Khankari worked as a clinical trial associate for a pharmaceutical company focusing on infectious disease and Phase III clinical trials. Ms. Khankari also worked as a research assistant analyzing qualitative data for multiple ongoing research studies at Boston Medical Center. She holds a master’s degree in public health with a major in epidemiology and biostatistics from Boston University and a bachelor’s degree in dental surgery.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.